Chronic pain psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
18 registered studies are counted for chronic pain. By compound: 17 psilocybin, 1 MDMA and 1 LSD. By registry status: 10 recruiting, 2 not yet recruiting, 1 enrolling by invitation, 2 active, not recruiting, 2 completed and 1 status not reported. By phase: 3 early phase 1, 6 phase 1, 7 phase 2, 1 not applicable and 1 not reported. Reported start years run from 2022 (earliest) to 2026 (latest).
Only studies of psychedelic compounds are counted here. Ketamine pain studies are mostly anaesthetic or analgesic research and are left out of this page. Experimentally induced pain in healthy volunteers and postoperative pain are not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 18 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 17 |
| MDMA | 1 |
| LSD | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 10 | 56% |
| Not yet recruiting | 2 | 11% |
| Enrolling by invitation | 1 | 6% |
| Active, not recruiting | 2 | 11% |
| Completed | 2 | 11% |
| Status not reported | 1 | 6% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 3 | 17% |
| Phase 1 | 6 | 33% |
| Phase 2 | 7 | 39% |
| Not applicable | 1 | 6% |
| Not reported | 1 | 6% |
Countries
Country is taken from the study's linked research site. 0 of 18 records have no country on file. The top 4 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 13 | 72% |
| Canada | 3 | 17% |
| United Kingdom | 1 | 6% |
| Netherlands | 1 | 6% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 12 |
| 2020 to 2023 | 6 |
Study design
- 17 interventional and 1 observational studies.
- Median planned or actual enrolment is 20 participants (range 10 to 45, across 18 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain | NCT07306364 | Not yet recruiting | Phase 2 | 2026-06-01 | Psilocybin |
| MDMA-assisted Therapy for Fibromyalgia | NCT06066853 | Recruiting | Early Phase 1 | 2026-04-01 | MDMA |
| Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids | NCT06827054 | Not yet recruiting | Phase 2 | 2026-03-15 | Psilocybin |
| Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study | NCT06988319 | Recruiting | Phase 1 | 2026-01-01 | Psilocybin |
| Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication | NCT05585229 | Recruiting | Phase 2 | 2025-10-27 | Psilocybin |
| Psilocybin as a Treatment for Chronic Pain in Smokers | NCT07118332 | Recruiting | Early Phase 1 | 2025-10-01 | Psilocybin |
| Psilocybin With Intracranial Neural Sensing | NCT06919640 | Enrolling by invitation | Phase 1 | 2025-06-01 | Psilocybin |
| Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | NCT06518720 | Recruiting | Phase 2 | 2025-04-01 | Psilocybin |
| Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN | NCT06731335 | Recruiting | Phase 2 | 2025-03-05 | Psilocybin |
| Psilocybin in Cancer Pain Study | NCT06001749 | Recruiting | Phase 2 | 2024-09-23 | Psilocybin |
| The Impact of Psilocybin on Pain in Fibromyalgia Patients | NCT06368492 | Recruiting | Not applicable | 2024-05-03 | Psilocybin, LSD |
| Psilocybin in Chronic Low Back Pain and Depression | NCT06355414 | Recruiting | Phase 1 | 2024-04-22 | Psilocybin |
| Psilocybin Therapy for Chronic Low Back Pain | NCT05351541 | Active, not recruiting | Phase 1 | 2023-12-01 | Psilocybin |
| Psilocybin-facilitated Treatment for Chronic Pain | NCT05068791 | Recruiting | Early Phase 1 | 2023-11-01 | Psilocybin |
| Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia | NCT05128162 | Completed | Phase 2 | 2023-09-27 | Psilocybin |
| Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain | NCT05506982 | Completed | Phase 1 | 2022-11-01 | Psilocybin |
| Psilocybin-assisted Therapy for Phantom Limb Pain | NCT05224336 | Active, not recruiting | Phase 1 | 2022-10-03 | Psilocybin |
| Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action | NCT05548075 | Status not reported | Not reported | 2022-08-15 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Suicidal ideation and suicide risk